The stock of Cymabay Therapeutics Inc (NASDAQ:CBAY) registered a decrease of 3.25% in short interest. CBAY’s total short interest was 6.30 million shares in November as published by FINRA. Its down 3.25% from 6.51M shares, reported previously. With 388,800 shares average volume, it will take short sellers 16 days to cover their CBAY’s short positions.
The stock decreased 0.78% or $0.07 during the last trading session, reaching $8.94. About 690,409 shares traded or 32.43% up from the average. CymaBay Therapeutics, Inc. (NASDAQ:CBAY) has risen 94.06% since November 14, 2017 and is uptrending. It has outperformed by 78.44% the S&P500.
CymaBay Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. The company has market cap of $531.39 million. It engages in developing seladelpar , a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout. It currently has negative earnings. The companyÂ’s product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes.
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Ratings Coverage
Among 2 analysts covering CymaBay Therapeutics (NASDAQ:CBAY), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CymaBay Therapeutics had 2 analyst reports since June 26, 2018 according to SRatingsIntel. Cantor Fitzgerald maintained CymaBay Therapeutics, Inc. (NASDAQ:CBAY) rating on Tuesday, June 26. Cantor Fitzgerald has “Buy” rating and $1600 target.
More notable recent CymaBay Therapeutics, Inc. (NASDAQ:CBAY) news were published by: Benzinga.com which released: “55 Biggest Movers From Yesterday” on November 14, 2018, also Nasdaq.com with their article: “CymaBay Therapeutics Presents Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC at …” published on November 13, 2018, Seekingalpha.com published: “CymaBay Therapeutics’ (CBAY) CEO Sujal Shah on Q3 2017 Results – Earnings Call Transcript” on November 07, 2018. More interesting news about CymaBay Therapeutics, Inc. (NASDAQ:CBAY) were released by: Benzinga.com and their article: “36 Stocks Moving In Tuesday’s Mid-Day Session” published on November 13, 2018 as well as Seekingalpha.com‘s news article titled: “Fortress Biotech among healthcare gainers; Novelion Therapeutics leads losers” with publication date: November 13, 2018.